HAE
Haemonetics Corporation
HAE has the edge over NVO overall on the model score.
NVO
Novo Nordisk A/S
NVO has slightly lower modeled downside risk, despite its lower overall score.
HAE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Under pressure |
HAE's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HAE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 25x | $56.99 | -54% |
| Fair | 41x | $93.28 | -24% |
| Current | 54x | $123 | — |
| Expensive | 66x | $150 | +22% |
Historical ranges are pointers, not guarantees.
HAE's PE is in its expensive range at 54x.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over HAE in the historical PE scenario, which offers more potential upside but is not a forecast.
HAE Forward outlook
There aren't enough analyst estimates for HAE to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HAE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.26 | -34% |
| Q2 2026 | $2.07 | -37% |
| Q1 2026 | $2.05 | -38% |
| Q4 2025 | $3.63 | +43% |
| Q3 2025 | $3.42 | +42% |
| Q2 2025 | $3.27 | +47% |
| Q1 2025 | $3.31 | +45% |
| Q4 2024 | $2.54 | +2.8% |
HAE earned $2.26 per share over the past year, down 34% from the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
HAE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +9.3% |
| Q2 2026 | $339.4M | +5.6% |
| Q1 2026 | $346.4M | +4.8% |
| Q4 2025 | $339M | -2.7% |
| Q3 2025 | $327.3M | -5.3% |
| Q2 2025 | $321.4M | -4.4% |
| Q1 2025 | $330.6M | -3.7% |
| Q4 2024 | $348.5M | +3.7% |
HAE's revenue has picked up after two years of holding roughly level: $358M last quarter, up 9.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +3.1 points |
| Q2 2026 | 17% | +0.2 points |
| Q1 2026 | -6.7% | -28 points |
| Q4 2025 | 20% | +2.9 points |
| Q3 2025 | 18% | +2.9 points |
| Q2 2025 | 17% | +4.9 points |
| Q1 2025 | 22% | +13 points |
| Q4 2024 | 17% | +3.3 points |
HAE's operating margin was 21% last quarter, up 3.1 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over HAE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over HAE on profitability, with a higher operating margin.
HAE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $113.3M | +6.6% |
| Q2 2026 | $44.4M | +226% |
| Q1 2026 | $53.3M | -47% |
| Q4 2025 | $87.2M | +148% |
| Q3 2025 | $106.3M | +170% |
| Q2 2025 | $13.6M | +$46.7M |
| Q1 2025 | $100.9M | +86% |
| Q4 2024 | $35.2M | +$58.1M |
HAE has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
HAE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +759K shares |
| 1 year | -2.5% | -1.2M shares |
| 3 years | -9.6% | -4.9M shares |
| 5 years | -9.7% | -5M shares |
| Available history | -10% | -5.2M shares |
HAE has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q1 2025 | $150M |
| Q4 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
HAE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 2.4x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 3.1x | Elevated |
HAE's net debt is about 3.0 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over HAE on leverage, with a lower net debt burden relative to earnings.
HAE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.5 | Overbought |
| Stochastic | 82.3 | Overbought |
HAE's weekly RSI is 79 (overbought) and its Stochastic is 82 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HAE PE vs Healthcare Sector
| Metric | HAE | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 110% above |
| PE % | 67 | 29 | 38 pts above |
HAE is trading at 54x earnings, a 110% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over HAE on valuation relative to its sector.
HAE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.0 | 5.8% above |
| 20 week MA | $101.3 | 21% above |
| 50 week MA | $80.9 | 52% above |
| 100 week MA | $72.9 | 68% above |
| 200 week MA | $78.4 | 57% above |
HAE has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
HAE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.9 | $118.8 | +2.4% |
| 2021 | $118.8 | $54.2 | -54% |
| 2022 | $54.2 | $79.2 | +46% |
| 2023 | $79.2 | $85.5 | +8% |
| 2024 | $85.5 | $77.6 | -9.3% |
| 2025 | $77.6 | $80.3 | +3.5% |
| 2026 YTD | $80.3 | $122.7 | +53% |
HAE has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.